PROM1 and neoplasm: As previously reported (10), we found that PROM1 (CD133) is strongly expressed in hematopoietic stem/progenitor cells (HSPCs), such as hematopoietic stem cells (HSCs), lymphoid-primed multipotent progenitors (LMPP), megakaryocyte progenitors (Prog Mk), and Prog B (Figure 1C), indicating that CD133 taken as a target may trigger the “on-target, off-tumor” myeloablative toxicity.